Türk Behçet hastalarının cinsiyet, HLA-B51 ve paterji testine göre klinik özelliklerinin değerlendirilmesi

Yıl 2019, Cilt: 52 Sayı: 3, 191 - 195, 21.12.2019

Nuh Ataş

Öz

Purpose: The clinical features of Behçet
disease (BD) are variable between race and country. Gender, pathergy test and
HLA B51 also have impact on clinical manifestations of BD. The aim of this
study is to investigate clinical evaulation of Turkish patients with BD
according to gender, HLA B51 and pathergy test.

Material and Method: 97 Turkish patients (59
males, 38 females) fulfilling the International Study
Group criteria for Behçet Disease 
were evaulated retrospectively.

Results

The mean age was 36,2 ± 11,1 years. The median (IQR: interquartile range) age at
diagnosis, duration of disease and delay in diagnosis were 26 (14), 7 (8) and 4 (8) years. Oral
aphtous ulcers were the most common manifestation (100%), followed by genital
ulcers (%67), skin findings (54,6%), ocular (51,5%) and vascular involvement
(24,7%), arthritis (23,7%) and neurologic involvement (14,4%). HLA B51 and
Pathergy test were positive in 70,1% and 39,2% of patients, respectively.
Genital ulcer, skin findings and articular involvement and HLAB51 positivity
were similiar between male and female gender. Pathergy positivity, ocular and
vascular involvement were more common in men. Skin findings more rare in
pathergy positive group.

Conclusion : The clinical manifestations
of BD in Turkish patients were influenced by gender, rahter than pathergy and
HLA B51 positivity.

Key words:
Behçet Disease, HLA B51, pathergy test, gender

 

Amaç: Behçet
hastalığının (BH) klinik özellikleri ülkeye ve ırk’a göre farklılık
gösterebilmektedir. Cinsiyet, paterji testi ve HLA B51 de BH’nın klinik
özelliklerini etkileyebilmektedir. Bu çalışmanın amacı; cinsiyet, HLA B51 ve
paterji testinin Türk Behçet hastalarının kliniğine etkisini değerlendirmektir.

Gereç ve Yöntem:
International Study Group kriterlerine göre BH tanısı almış 97 Türk hasta
retrospektif olarak değerlendirildi.

Bulgular:
Ortalama yaş 36.2
± 11.1 yıl idi. Medyan (ÇAA:çeyreklerarası aralık) tanı yaşı, hastalık süresi
ve tanıda gecikme yaşı; 26 (14), 7 (8) and 4 (8) yıl idi. Oral aftöz ülserler
en sık gözlenen bulguydu(%100). Oral ülserleri, genital ülserler (%67), cilt
bulguları (%54,6), oküler (%51,5) ve vasküler tutulum (%24,7), artrit (%23,7) ve
nörolojik tutulum (%14,4) izlemekteydi. HLA B51 ve paterji testi, hastaların %
70,1’inde ve %39,2’sinde pozitifti. Genital ülser, cilt bulguları, artiküler
tutulum ve HLA B51 pozitifliği erkek ve kadın cinsiyette benzerdi. Paterji
pozitifliği, oküler ve vasküler tutulum erkeklerde daha fazlaydı. Paterji
pozitif olan grupta cilt bulguları daha nadirdi.

Sonuç: Türk
Behçet hastalarının klinik özellikleri cinsiyetten belirgin olarak
etkilenirken, paterji ve HLA B51 pozitifliğinden pek etkilenmemektedir.

Anahtar
kelimeler: Behçet hastalığı, HLA B51, paterji testi, cinsiyet

Anahtar Kelimeler

Behçet hastalığı, HLA B51, paterji testi, cinsiyet

Kaynakça

• 1. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol. 2003;42(5):346-51.
• 2. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54(3):213-20.
• 3. Onder M, Gurer MA. The multiple faces of Behcet's disease and its aetiological factors. J Eur Acad Dermatol Venereol. 2001;15(2):126-36.
• 4. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet's disease: from East to West. Clin Rheumatol. 2010;29(8):823-33.
• 5. Wang LY, Zhao DB, Gu J, Dai SM. Clinical characteristics of Behcet's disease in China. Rheumatol Int. 2010;30(9):1191-6.
• 6. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341(17):1284-91.
• 7. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on patients with Behcet's disease in Korea. J Korean Med Sci. 2003;18(2):231-5.
• 8. Hamzaoui A, Houman MH, Massouadia M, Ben Salem T, Khanfir MS, Ben Ghorbel I, et al. Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet's disease in Tunisian patients. Eur J Intern Med. 2012;23(4):347-9.
• 9. Assar S, Sadeghi B, Davatchi F, Ghodsi SZ, Nadji A, Shahram F, et al. The association of pathergy reaction and active clinical presentations of Behcet's disease. Reumatologia. 2017;55(2):79-83.
• 10. Ryu HJ, Seo MR, Choi HJ, Baek HJ. Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51. Korean J Intern Med. 2018;33(5):1025-31.
• 11. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335(8697):1078-80.
• 12. Balta I, Akbay G, Kalkan G, Eksioglu M. Demographic and clinical features of 521 Turkish patients with Behcet's disease. Int J Dermatol. 2014;53(5):564-9.
• 13. Yavuz S, Ozilhan G, Elbir Y, Tolunay A, Eksioglu-Demiralp E, Direskeneli H. Activation of neutrophils by testosterone in Behcet's disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S46-51.
• 14. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. Cell Biochem Funct. 2006;24(4):353-6.
• 15. Guzelant G, Ozguler Y, Esatoglu SN, Karatemiz G, Ozdogan H, Yurdakul S, et al. Exacerbation of Behcet's syndrome and familial Mediterranean fever with menstruation. Clin Exp Rheumatol. 2017;35 Suppl 108(6):95-9.
• 16. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287-96.
• 17. Yazici H, Tuzun Y, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A. The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behcet's disease in Turkey. J Rheumatol. 1980;7(2):206-10.